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Mutations in SEC24D, Encoding a Component
of the COPII Machinery, Cause a Syndromic Form
of Osteogenesis Imperfecta
Lutz Garbes,1,2,3,14 Kyungho Kim,4,14 Angelika Rieß,5,14 Heike Hoyer-Kuhn,6 Filippo Beleggia,1,2,7
Andrea Bevot,8 Mi Jeong Kim,9 Yang Hoon Huh,9 Hee-Seok Kweon,9 Ravi Savarirayan,10 David Amor,10
Purvi M. Kakadia,11 Tobias Lindig,12 Karl Oliver Kagan,13 Jutta Becker,1 Simeon A. Boyadjiev,4
Bernd Wollnik,1,2,7 Oliver Semler,6 Stefan K. Bohlander,11 Jinoh Kim,4,* and Christian Netzer1,*
As a result of a whole-exome sequencing study, we report three mutant alleles in SEC24D, a gene encoding a component of the COPII
complex involved in protein export from the ER: the truncating mutation c.613C>T (p.Gln205*) and the missense mutations
c.3044C>T (p.Ser1015Phe, located in a cargo-binding pocket) and c.2933A>C (p.Gln978Pro, located in the gelsolin-like domain). Three
individuals from two families affected by a similar skeletal phenotype were each compound heterozygous for two of thesemutant alleles,
with c.3044C>T being embedded in a 14Mb founder haplotype shared by all three. The affected individuals were a 7-year-old boy with a
phenotype most closely resembling Cole-Carpenter syndrome and two fetuses initially suspected to have a severe type of osteogenesis
imperfecta. All three displayed a severely disturbed ossification of the skull andmultiple fractures with prenatal onset. The 7-year-old boy
had short stature and craniofacial malformations including macrocephaly, midface hypoplasia, micrognathia, frontal bossing, and
down-slanting palpebral fissures. Electron and immunofluorescence microscopy of skin fibroblasts of this individual revealed that ER
export of procollagen was inefficient and that ER tubules were dilated, faithfully reproducing the cellular phenotype of individuals
with cranio-lentico-sutural dysplasia (CLSD). CLSD is caused by SEC23A mutations and displays a largely overlapping craniofacial
phenotype, but it is not characterized by generalized bone fragility and presented with cataracts in the original family described.
The cellular and morphological phenotypes we report are in concordance with the phenotypes described for the Sec24d-deficient fish
mutants vbi (medaka) and bulldog (zebrafish).Osteogenesis imperfecta (OI, types I to XV [MIM 166200,
166210, 259420, 166220, 610967, 613982, 610682,
610915, 259440, 613848, 610968, 613849, 614856,
615066, and 615220]) is a heterogeneous group of disor-
ders associated with reduced bone mass, increased bone
fragility, bone deformity, and growth deficiency. Up to
90% of individuals with a classical OI phenotype have het-
erozygosity for mutations in the genes COL1A1 (MIM
120150) or COL1A2 (MIM 120160).1 These genes encode
for the two pro-alpha chains of type I collagen, which co-
translationally translocate into the lumen of the endo-
plasmic reticulum (ER). Within the ER, several molecular
chaperons and enzymes are required for post-translational
procollagen folding and modification.2,3 The majority of
the 11 genes in which mutations have been identified in
autosomal-recessive types of OI encode for proteins with
a role in these processes.4–6 Procollagen export from the
ER occurs via membrane-bound vesicles or carriers that
are generated by a set of cytoplasmic coat proteins called
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432 The American Journal of Human Genetics 96, 432–439, March 5Several rare syndromes have been described that clini-
cally overlap with OI but display additional symptoms.
Two well-known examples are Bruck syndrome (MIM
259450 and 609220), previously known as ‘‘OI with
congenital joint contractures,’’9 and osteoporosis-pseudo-
glioma syndrome (MIM 603506), first described as ‘‘ocular
form of OI.’’10,11 In 1986, Cole and Carpenter described
two infants with bone deformities and multiple fractures
reminiscent of OI who also had ocular proptosis with
orbital craniosynostosis, hydrocephalus, and distinctive
facial features (MIM 112240).12 A biochemical collagen
analysis was performed in one of these infants and showed
normal results. Subsequently, four additional individuals
with Cole-Carpenter syndrome have been described in
the literature.13–16 Themolecular cause andmode of inher-
itance are unknown.
At the Tu¨bingen University Hospital, we have treated a
boy with a syndromic form of OI that we clinically classi-
fied as Cole-Carpenter syndrome, based on the history of
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Figure 1. Photographs and CT Scans of
the Affected Individual from Family 1
(A) Affected individual from family 1 at the
age of 7 years. Note facial dysmorphism
with down-slanting palpebral fissures, hy-
pertelorism, dysplastic right ear, and pec-
tus excavatus.
(B) Lateral view. Note mid-face hypoplasia,
micrognathia, frontal bossing, and
dysplastic right ear.
(C) Three-dimensional CT scan of the cra-
nium at the age of 14 months. Note wide
sagittal suture with a broad ossification
defect fronto-parietal apical. Suturametop-
ica is displaced to the bottom, as indicated
by surrounding wormian bones. Coronal
sutures, lambda sutures, and temporal su-
tures appear narrow and with premature
ossification pattern without clear synos-
tosis, but with multiple wormian bones
enclosed.
(D) Lateral view of a cranial CT scan taken
at age 4 years and 4 months, with multiple
wormian bones highlighted in different
colors. Note an intraparietal suture on the
left side (described as unilateral intraparie-
tal suture30). The large ossification defect
fronto-parietal apical persisted. The sphe-
noid wings appear with an increased den-
sity and with multiple erosions.distinct craniofacial malformations. The detailed clinical
history of this individual is summarized in the Supple-
mental Data. When he was 7 years old, we recruited the
boy and his unaffected parents (family 1) for a research
project on OI to identify the underlying molecular mecha-
nism. The study was approved by the Ethics Committee of
the LMU Munich, and written informed consent was ob-
tained from the affected individuals’ parents for molecular
genetics studies. At this age, the boy had moderately re-
duced bone mineral density (2.0 SD in a DXA whole-
body measurement, Table S1). He had been treated with a
total of 23 cycles of intravenous bisphophonates. He dis-
played macrocephaly (head circumference > 97th percen-
tile) with postnatal onset and short stature, and had normal
mobility, intelligence, and hearing. His facial features were
highly reminiscent of Cole-Carpenter syndrome (Figures
1A and 1B; see Figure S1 for comparison of the facial fea-
tures with those of the individuals originally described by
Cole and Carpenter). The most salient clinical symptom
was a large fronto-parietal apical ossification defect of the
skull (Figure 1C), which made it necessary for the child to
wear a helmet during physical activities. Cranial CT scans
that had been taken at the ages of 1 year and 4 years also
documented dilated ventricles, multiple wormian bones
(Figure 1D), and narrow coronal, lambda, and temporal su-The American Journal of Humantures with a premature ossification
pattern. Upon recruitment to our
research project, the boy was assessed
in the specialized unit for OI at the
Children’s Hospital of the Universityof Cologne by the in-house standard protocol. The clinical
findings are summarized in Table S1. Mutations in the
genes COL1A1 and COL1A2 as well as in eight other genes
associatedwithOI or increased bone fragility were excluded
by Sanger sequencing of genomic DNA (see Table S2 for de-
tails). Bone mineral density of the parents measured by
DXA and peripheral quantitative computertomography
was in the normal age-adjusted range.
We performed whole-exome sequencing (WES) of the
affected boy and his unaffected parents. Exonic and adja-
cent intronic regions were enriched from genomic DNA
derived from peripheral blood via the 50 MB SureSelect
All Exon V4 target enrichment kit from Agilent Technolo-
gies, and paired-end sequencing was performed on the Illu-
mina platform (Genome Analyzer IIx or HiSeq2000). The
mean on-target coverage was 52 for the affected individual
from family 1 and for his father, and 54 for his mother. The
percentage of the WES target covered by at least 10 reads
was 87% for the affected individual and for his mother
and 86% for his father. Alignment against the GRCh37 hu-
man reference genome was performed with a Burrows-
Wheeler Aligner (BWA, v.0.6.2), PCR-duplicates marking
and removal with Picard (v.1.84), indel realignment, base
quality recalibration, and variant calling with the Genome
Analysis Toolkit (GATK, v.2.3-4), and annotation withGenetics 96, 432–439, March 5, 2015 433
Figure 2. Validation of the SEC24D Mutations by Sanger Sequencing of Genomic DNA
Pedigrees of the two analyzed families and electropherograms of the respective SEC24Dmutations in exons 5, 22, and 23 are shown. In
family 1, each parent carries one of the two mutations and the affected son (I-4) is compound heterozygous for the SEC24Dmutations
c.613C>T (p.Gln205*) and c.3044C>T (p.Ser1015Phe). The healthy sister of the affected individual did not carry either of the two mu-
tations. Also in family 2, each parent is heterozygous carrier of one of the two SEC24Dmutations and both affected fetuses (II-3 and II-4)
are compound heterozygous for c.2933A>C (p.Gln978Pro) and c.3044C>T (p.Ser1015Phe). The healthy sister (II-5) is a heterozygous
carrier of only one of these mutations. The red arrows in the electropherograms indicate either the mutation or the respective position
in the wild-type sequence. In addition, for several family members the haplotype combination at the SEC24D locus is shown, and 15 of
the 166 consecutive good-quality SNPs used for reconstructing the 14 Mb disease haplotype are depicted. Note that individuals I-2, I-4,
and II-1 share the SEC24D mutation c.3044C>T and an identical haplotype between the SNPs rs6533681 and rs2255457. The dashed
line between I-2 and II-2 indicates that the mutation c.3044C>T is a founder mutation inherited from a distant common ancestor.Annovar (v.2013_Feb21). The resulting variants were
filtered to exclude the following: (1) variants with a MAF
> 0.001 in dbSNP, in the Exome Variant Server, the 1000
Genomes Project, or in our in-house database and (2) var-
iants that were not predicted to affect protein sequence or
exon splicing.
Filtering the WES data for deleterious variants under an
autosomal-recessive disease model provided potentially
causative variants in five candidate genes (Table S3).
Among these, SEC24D (MIM 607186; RefSeq accession
number NM_014822.2) was a perfect candidate for several
reasons. First, SEC24D is a component of the COPII com-
plex involved in protein export from the ER. The COPII
complex is responsible for ER export of procollagen,
among many other secretory proteins.8,17 Second, muta-
tions in SEC23A (MIM 610511), encoding a binding part-
ner of SEC24D in the COPII complex, cause the auto-
somal-recessive disorder cranio-lenticulo-sutural dysplasia
(CLSD, also known as Boyadjiev-Jabs syndrome [MIM
607812]).18–20 CLSD is characterized by facial dysmor-434 The American Journal of Human Genetics 96, 432–439, March 5phism, cataracts, and skeletal defects. Intriguingly, large
skull ossification defects as observed in the affected indi-
vidual from family 1 are one of the hallmarks in CLSD,
and moreover, one of the seven individuals with CLSD
described in the literature displayed mild osteopenia as
an additional symptom.20 Third, the medaka mutant vbi,
caused by a sec24d nonsense mutation, is characterized
by short body length, OI, and craniofacial malforma-
tions—including an impaired ossification of the neurocra-
nium—due to defective collagen secretion into the extra-
cellular matrix.21 Thus, this animal model recapitulates
in detail the phenotype of the affected individual from
family 1 (of note, Sec24d-null mice are embryonic lethal
prior to skeletal development22).
Sanger sequencing confirmed compound heterozygosity
for a SEC24D nonsense mutation (c.613C>T [p.Gln205*])
and for a missense mutation (c.3044C>T [p.Ser1015Phe])
in the affected individual from family 1 (Figure 2). The
missense mutation affects a highly conserved amino acid
(Figure S2A), is absent on ~13,000 chromosomes from, 2015
the Exome Variant Server (EVS), is not annotated in the
1000 Genomes project, is not listed in the ExAc Browser
of the Exome Aggregation Consortium, and is predicted
to be deleterious by the algorithms MutationTaster, Poly-
Phen-2, and SIFT. The parents were confirmed to be hetero-
zygous for the nonsense mutation (father) and for the
missense mutation (mother). In the non-affected sibling
of the affected boy, compound heterozygosity was ex-
cluded. Finding compound-heterozygousmutations rather
than a homozygous disease-causing mutation fitted the
fact that the father of the affected individual was of Greek
and his mother of Southern German descent.
At the time we recruited family 1, we also offered WES as
part of the same OI research project to a healthy German
couple who had chosen to terminate two pregnancies
with female fetuses suspected to be affected by a severe
type of OI. Written informed consent for molecular ge-
netics studies was obtained from both individuals. The
couple (family 2) was non-consanguineous and lived in
the same region in southwestern Germany as family 1. Mu-
tations in the genes COL1A1 and COL1A2 and in nine
other genes associated with OI or increased bone fragility
were excluded by Sanger sequencing of genomic DNA of
one of the fetuses (see Table S2 for details). Because there
was not enough high-quality fetal DNA available for WES
analyses in family 2, we performed WES on genomic
DNA from both parents and searched for deleterious het-
erozygous variants in the same gene in both parental
WES datasets, assuming an autosomal-recessive mode of
inheritance of the phenotype. The mean on-target co-
verage was 47 and 49, and the percentage of theWES target
covered by at least 10 reads was 93% and 94% for the
mother and for the father, respectively.
Filtering theWES datasets of family 2 (mother and father
of the affected fetuses) for heterozygous deleterious muta-
tions in the samegene resulted ina list of 17 candidate genes
(Table S4). Unexpectedly, SEC24D was among these can-
didates, with the father being heterozygous for the same
missense mutation c.3044C>T (p.Ser1015Phe) we had
identified in family 1. The mother was heterozygous for
the SEC24Dmissensemutation c.2933A>C (p.Gln978Pro).
This mutation also affects a highly conserved amino acid
(Figure S2B), is absent on ~13,000 chromosomes from the
Exome Variant Server (EVS), is not annotated in the 1000
Genomes project, is not listed in the ExAc Browser of the
Exome Aggregation Consortium, and is predicted to be
deleterious by the algorithms MutationTaster, PolyPhen-2,
and SIFT. Only one other gene appeared on the candidate
gene lists for both families 1 and 2: LMO7 (MIM 604362).
Sanger sequencing revealed that the affected fetuses had
discordant LMO7 genotypes, excluding this gene from the
list of candidates. Further analyses by Sanger sequencing
confirmed heterozygosity for the SEC24D mutations in
the parents and, most importantly, demonstrated that
both affected fetuses were compound heterozygous for
the SEC24D mutations c.3044C>T (p.Ser1015Phe) and
c.2933A>C (p.Gln978Pro). The healthy 10-year-old sisterThe Ameof the fetuses was a heterozygous carrier of only one of
the two mutations (Figure 2). Because the mother of the
affected boy of family 1 and the father of the fetuses of fam-
ily 2 both descended from families living in southwestern
Germany (central region of Baden-Wu¨rttemberg), we hy-
pothesized that the mutation c.3044C>T (p.Ser1015Phe)
might be a founder mutation. To test this hypothesis, we
used SNP genotypes from the WES datasets to reconstruct
the haplotypes in which the mutations were embedded.
We identified a haplotype extending for 14 Mb, supported
by 166 consecutive good-quality SNPs between rs6533681
and rs2255457 (chr4: 114,309,589–128,554,154), which
was shared by the affected individual from family 1, by
his mother, and by the father of the affected fetuses from
family 2 (Figure 2). Hence, this haplotype analysis clearly
demonstrated that the mutation c.3044C>T (p.Ser1015-
Phe) is indeed a founder mutation, strongly suggesting
that it is disease causing in both families.
We collected more detailed clinical information on the
affected fetuses. Both had—in addition to multiple frac-
tures of the long bones and mildly bent extremities—a
thin, poorly ossified skull upon ultrasound analysis in
the 23rd and 20th week of gestation. In one of the fetuses,
an autopsy was performed and X-rays of the entire body
were taken (Figure S4). These analyses revealed that the ex-
tremities, the vertebrae, the base of the skull, and the facial
bones were almost regularly ossified, whereas the ossifica-
tion of the calvarium was strongly reduced and largely ab-
sent. The ribs were thin, and single fractures were noted,
but the thorax was not severely hypoplastic, suggesting
that the skeletal defects were non-lethal. Taken together,
these two fetuses not only shared one of the SEC24D
mutations with the affected individual from family 1, but
also the highly unusual clinical finding of a severe ossifica-
tion defect of the calvarium contrasted by a normal ossifi-
cation of the skull base and only mildly disturbed ossifica-
tion and shape of the rest of the skeleton. We concluded
that all three affected individuals from these two families
had the same skeletal disorder, and that the substitutions
p.Gln205*, p.Ser1015Phe (resulting from the founder mu-
tation), and p.Gln978Pro are disease causing.
To elucidate the underlying cellular pathogenesis, we
analyzed cultured skin fibroblasts from family 1 (affected
individual and both parents). Functional studies in indi-
viduals with the SEC23A-associated disorder CLSD had
noted inefficient ER export of type I procollagen.18,20
Thus, we expected that the SEC24D mutations block ER
export of type I procollagen, resulting in accumulation of
collagen in the ER in the cells of the affected individual.
To test whether the ER export of procollagen is altered,
we monitored the intracellular distribution of procollagen
by employing immunofluorescent labeling with anti-
bodies for a type I procollagen, COL1A1, and the ER
marker PDI. The cells of the affected individual retained
more procollagen in the ER than the control fibroblasts
with significant statistical difference (Figure 3). These
data indicate that ER export of procollagen is compromisedrican Journal of Human Genetics 96, 432–439, March 5, 2015 435
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Figure 3. Retention of Procollagen in
the ER
(A) Double immunofluorescent labeling of
control and the affected individual’s fibro-
blasts for type I procollagen and protein
disulfide isomerase (PDI), an ER marker.
Images were obtained by standard con-
focal microscopy.
(B) The number of cells with an indicated
overlap of procollagen with PDI was
shown. Standard deviations from three in-
dependent experiments are shown in pa-
rentheses.
(C) ImageJ was used to normalize fluores-
cent intensities of procollagen with those
of PDI from the images obtained via
confocal microscopy. Procollagen is re-
tained more in the fibroblasts of the
affected individual (light blue) than in
the control fibroblasts (gray) with statisti-
cal significance (Student’s t test, p ¼
0.0001, n ¼ 467 cells for control fibroblast,
n ¼ 554 cells for the affected individual’s
fibroblasts).in the fibroblasts of the affected individual. However, con-
ventional immunoblotting did not yield conclusive results
on cellular accumulation of procollagen (data not shown),
suggesting that there is no gross accumulation of procolla-
gen in the fibroblasts of the affected individual. Thus, we
conclude that ER export of procollagen is mildly defective
in these fibroblasts.
Depletion of COPII components causes ER retention
of cargo molecules, leading to dilation of ER cisternae. To
monitor an ER export defect, we measured the thickness of
ER cisternae via electron micrographs in a blinded analysis
setting (Figure 4). Because ER tubules range from about
100to150nminthickness in thevastmajorityof cells, those
that are thicker than 150 nm were defined as distended
(Figure 4E). Based on this criterion, about 18% of control,
22%ofmaternal, 13%ofpaternal, and63%of theER tubules
of the affected individual were dilated. A statistical analysis
confirmed that the ER tubules of the cells from the affected
individual were significantly distended, compared to the
control and parental cells (see legend to Figure 4). These re-
sults clearly support the notion that ER export is defective
in the fibroblasts of the affected individual.
COPII-coated vesicles, which play a critical role in ex-
porting themajority of proteins from the ER, are composed
of three proteins complexes: SAR1, SEC23/SEC24, and
SEC13/SEC31.17 These COPII proteins deform the lipid
bilayer into buds at ER exit sites, load cargo molecules
into the nascent buds, and complete vesicle scission. There
exist multiple paralogs for each COPII gene except SEC13
in vertebrates. In particular, there are four SEC24 paralogs
(SEC24A, SEC24B, SEC24C, and SEC24D). SEC24 is mainly436 The American Journal of Human Genetics 96, 432–439, March 5, 2015responsible for sorting cargo mole-
cules through direct or indirect inter-
actions during COPII vesicle assem-
bly. Defects in SEC24, therefore, willcause inefficient loading of cargo molecules into COPII
vesicles, resulting in accumulation of cargo molecules in
the ER. Each SEC24 possesses multiple cargo-binding
sites,23 which increases the repertoire of cargo molecules
packaged into COPII vesicles.
We analyzed the structure of SEC24D to obtain further
insights into the functional effects of the identified muta-
tions (Figure 5). The SEC24D Ser1015 residue substituted
in families 1 and 2 is highly conserved in SEC24s (Fig-
ure S2A). It is located near the IxM pocket of SEC24D.23
This pocket is responsible for recognizing the IxM ER
export signal. We expect that the p.Ser1015Phe substitu-
tion disrupts the IxM pocket and interferes with binding
to the IxM signal. Immunoblot analysis of SEC24D in fam-
ily 1 showed that the levels of SEC24D were reduced in the
fibroblasts of the affected individual as well as in the
paternal fibroblasts (Figure 5C). Probably, these reductions
are caused by haploinsufficiency of the p.Gln205* allele.
The SEC24D Gln978 residue substituted in family 2 is
located in an alpha helix of the gelsolin-like domain of
SEC24D. Intriguingly, Gln978 is found in the structurally
equivalent region where the CLSD-causing SEC23A sub-
stitutions p.Met702Val and p.Phe382Leu are positioned
(Figure 5D). Previous studies have established that
Met702 and Phe382 of SEC23A constitute a portion of
the SEC31-binding groove.24,25 Although SEC23 is mainly
responsible for the interaction between the SEC23-SEC24
complex and SEC31, it is possible that the region including
Gln978 of SEC24D might also contribute to SEC31 bind-
ing. Alternatively, the p.Gln978Pro substitution might
simply destabilize SEC24D, resulting in a reduction of
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Figure 4. Dilation of ER in the Fibroblasts of the Affected Indi-
vidual from Family 1
(A–D) Micrographs of thin-section electron microscopy for fibro-
blasts from control (A), affected individual (B), mother of affected
individual (C), and father of affected individual (D). Tubular ER el-
ements studded with ribosomes are indicated by arrowheads. Scale
bars represent 500 nm.
(E) Summary of the thickness of ER tubules in fibroblasts. 100 nm
in the x axis represents a thickness that is larger than 50 nm but
equal to or less than 100 nm. The average thickness of the tubules
is about 189 nm, 120 nm, 116 nm, and 125 nm for the cells from
the affected individual (light blue), control (yellow), father (or-
ange), and mother (gray), respectively. The ER tubules of the fibro-
blasts from the affected individual were thicker than those of other
fibroblasts with statistical significance according to a one-way
ANOVA with Tukey’s honest significant difference test (p < 0.01;
n ¼ 183 tubules for control, 212 for father, 171 for mother, and
181 for the affected individual).
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Figure 5. Position of the Mutant Residues in the 3D Structure of
SEC24D
Note that the available human SEC24D structures were solved
with the isoform 2 (O94855-2) (1,033 aa). Here we used the
nomenclature of the isoform 1 (O94855-1) (1,032 aa) of SEC24D
because this form has been chosen as the canonical sequence in
the databases. PDB 3EFO structure was used.23
(A) Gln978 (red, upper panel) is located in the gelsolin-like
domain of SEC24D. The location of Gln978 SEC24D is structurally
similar to that of Met702 (yellow) and Phe382 (blue) of SEC23A. A
more detailed structural comparison was shown in (D). Ser1015
(red, lower panel) is found in the IxM pocket (I, x, and M stand
for Ile, any amino acid, and Met). A fragment of syntaxin 5
(magenta) contains an IxM signal. A more detailed structure is
shown in (B).
(B) The helical domain of SEC24D is shown. Ser1015 (red) is
located in an a-helix (yellow) that contains key residues
(Leu1020 and His1024, blue) of the IxM pocket. Additional key
residues (Leu833 and Leu835, blue) of this pocket are located in
a b-strand (yellow).
(C) Total lysates (10 mg) of indicated fibroblasts derived from fam-
ily 1 were prepared, resolved by SDS-PAGE, and processed for
immunoblotting. Control foreskin fibroblasts were obtained
from the American Type Culture Collection (ATCC, CRL-091). Ri-
bophorin 1 (an ER-resident protein) was probed as loading con-
trols. Bands (open arrowheads) below the main SEC24D band
probably represent partial degradation products of SEC24D or
nonspecific proteins.
(D) The gelsolin-like, the helical, and the trunk domains of
SEC24D (left) and SEC23A (right) were colored blue, cyan, and
green, respectively. CLSD-linked mutations were colored red.
Met702 and Phe382 of SEC23A constitute a part of the SEC31-
binding pocket.24,25the levels of SEC24D. Unfortunately, skin fibroblasts from
family 2 are not available, and therefore we currently
cannot test these hypotheses.
Summing up the results of the cellular studies, we have
shown that ER export of procollagen was inefficient in
the skin fibroblasts obtained from the affected individual
of family 1, and ER tubules were dilated, faithfully repro-
ducing the cellular phenotypes of individuals with CLSD
resulting from SEC23A mutations.18,20,24,25 These results
are also in concordance with the cellular phenotypeThe Ameobserved in the sec24d-deficient medaka fish vbi21 and ze-
brafish bulldog.26
The similarities between SEC23A and SEC24Dmutant fi-
broblasts prompted us to ask whether the diagnosis of
Cole-Carpenter syndrome is the best clinical classification
for the phenotype we report. As mentioned above, the
affected individual from family 1 also shared many of therican Journal of Human Genetics 96, 432–439, March 5, 2015 437
key symptoms described for CLSD (but has no detectable
SEC23A mutation), and the facial phenotype was very
similar. However, a cataract, one of the leading symptoms
of CLSD, which presented within the first years of life in
the original family described,19 was missing in the affected
individual we report. Upon thorough ophthalmologic ex-
amination, there was also no evidence of a double-ring
sign of the lens, as described in an individual with a single
heterozygous SEC23A missense mutation (i.e., without a
detectable second mutant allele) who had craniofacial,
skeletal, and cellular features characteristic of CLSD and
who in addition had osteopenia and macrocephaly.20
Interestingly, this individual with a heterozygous SEC23A
mutation (and no detectable SEC24D mutation, data not
shown) also had esotropia and optic nerve hypoplasia,
and the affected individual from family 1 had strabism
and small optic discs of normal color. Nevertheless,
increased bone fragility with prenatal onset, one of the
clinical hallmarks of all three affected individuals we
report, has not been described for individuals with
SEC23A mutations. We therefore regard the phenotype
we report as a clinical entity that can be distinguished
from the phenotype of the individuals with CLSD
described in the literature, although the symptoms clearly
overlap.
We reviewed all five published case reports of Cole-Car-
penter syndrome12–16 and compared the clinical and
radiological findings of the six described individuals in
detail with the affected individual from family 1 (Table
S5). Information on skull ossification defects—one of the
most obvious symptoms in the affected individuals we
describe—are incomplete or missing in some of the re-
ports, but overall, the similarities are striking, and con-
sequently, we still consider Cole-Carpenter syndrome to
be the best classification for the phenotype. However, we
were unable to obtain DNA samples from the originally re-
ported individuals to genetically substantiate this classifi-
cation, and Sanger sequencing failed to identify SEC24D
mutations in the individual with Cole-Carpenter syn-
drome described by Amor et al.13 (Figure S1C; note that
we also did not detect any SEC23A mutation in this indi-
vidual). This suggests that there is further genetic heteroge-
neity for Cole-Carpenter syndrome. In any case, there is
obviously a spectrum of clinically overlapping skeletal dis-
orders that ranges from CLSD to Cole-Carpenter syndrome
and might also include other diseases. Further genetic,
clinical, and functional studies are needed to comprehen-
sively describe the phenotypic spectrum of these syn-
dromes and to elucidate the molecular links between
them. Because generalized bone fragility, apparently due
to a defect in intracellular collagen transport, was one of
the leading symptoms in the individuals with SEC24Dmu-
tations described here, we consider it to be reasonable to
place this type of Cole-Carpenter syndrome into the osteo-
genesis imperfecta and decreased bone density group, as
suggested by the revised Nosology and Classification of
Genetic Skeletal Disorders.27438 The American Journal of Human Genetics 96, 432–439, March 5In conclusion, we report three mutant SEC24D alleles,
one of them being a founder mutation shared by all three
affected individuals from two families and another one
leading to a premature stop codon, in a rare autosomal-
recessively inherited skeletal disorder characterized by
pre- and postnatal bone fragility, skull ossification defects,
craniofacial dysmorphism, and short stature. The causal
role of SEC24D mutations is strongly supported by the
morphological and cellular phenotype observed inmedaka
and zebrafish models with truncating mutations in the or-
tholog sec24d and in humans with mutations in SEC23A.
Thus, we assign the fourth human phenotype to germline
mutations in components of the COPII machinery.18,28,29Supplemental Data
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